Midlertidigt ændring af emissionstillæg og indløsningsfradrag for Investeringsforeningen Danske Invest Select
På grund af uro på de finansielle markeder, er emissionstillæg/indløsningsfradrag midlertidigt ændret for en enkelt afdeling i Investeringsforeningen Danske Invest Select.
Fra og med handelsdag d. 16. marts 2023 foretages følgende ændringer:
Emissionstillæggets sammensætning og maksimale størrelse i procent:
| ISIN | Afdeling/andelsklasse | Kurtage og alle øvrige direkte handelsudgifter ved køb af instrumenter, ca. | Øvrige markedsafledte udgifter ved køb af instrumenter, ca. | I alt, maksimalt | Ændring ift. gældende satser |
| DK0016303936 | Euro Investment Grade Corporate Bonds Restricted, klasse DKK d | 0,00 | 1,00 | 1,00 | 0,50 |
Indløsningsfradragets sammensætning og maksimale størrelse i procent:
| ISIN | Afdeling/andelsklasse | Kurtage og alle øvrige direkte handelsudgifter ved salg af instrumenter, ca, | Øvrige markedsafledte udgifter ved salg af instrumenter, ca, | I alt, maksimalt | Ændring ift, gældende satser |
| DK0016303936 | Euro Investment Grade Corporate Bonds Restricted, klasse DKK d | 0,00 | 1,00 | 1,00 | 0,50 |
Med venlig hilsen
DANSKE INVEST
MANAGEMENT A/S
Tina Hjorth Hetting
Head of Fund Products
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division6.5.2024 12:00:00 CEST | Press release
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health Division. This enhancement is led by John Boshart, a distinguished figure in animal health with profound experience from his tenures at Pfizer Animal Health and Zoetis. His arrival signifies a strategic consolidation of talent and expertise aimed at redefining standards within the veterinary sector. Brains Bio’s Animal Health Division is empowered by the unique properties of its THC-free CBD API, which boasts an ultra-low detection limit of 0.000006%. This EU-GMP Certified API is pivotal in clinical and preclinical studies, including a Phase III Clinical Trial, highlighting its potential for therapeutic applications in veterinary medicine. The CBD API is supported by rigorous regulatory credentials, including ICH-Q7 compliance, an actively maintained EU Active Substance Master File (ASMF), and a
Fejl i indre værdi i Investeringsforeningen Sparinvest6.5.2024 11:47:47 CEST | pressemeddelelse
Det skal oplyses, at der den 3. maj i perioden 09:45 til 10:55, er sket en fejl i beregningen af indre værdi for nedenstående afdeling. Indre værdi for nedenstående afdeling har i perioden været undervurderet. OrderbookcodeAfdelingsnavnISINPåvirkningSPIUSGKLSparindex INDEX USA Growth KLDK0010298272-0,68% Eventuel henvendelse vedrørende denne meddelelse kan rettes til NPA.PM@nykredit.dk eller CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze
Prepayments, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | Press release
To Nasdaq Copenhagen A/SExecutive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 6 May 2024 Company Announcement No 34/2024 Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 3 May 2024. Please find the data in the attached file. The information will also be available on www.rd.dk. Yours sincerely The Executive Management Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068. Attachments Nr 34_Ekstraordinaere indfrielser_ukBilag til selskabsmeddelelse nr 34-2024
Ekstraordinære indfrielser, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | pressemeddelelse
Til Nasdaq Copenhagen A/SDirektionen Bernstorffsgade 40 1577 København V www.rd.dk Telefon 7012 5300 6. maj 2024 Selskabsmeddelelse nummer 34/2024 Ekstraordinære indfrielser, Realkredit Danmark A/S I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 3. maj 2024. Oplysningerne fremgår af vedhæftede datafil. Oplysningerne vil desuden kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk. For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside. Med venlig hilsen Direktionen Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68. Vedhæftede filer Nr. 34_Ekstraordinaere indfrielser_dkBilag til selskabsmeddelelse nr 34-2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia6.5.2024 11:00:00 CEST | Press release
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4 It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentia